By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Paced by growth in its Analytical Technologies segment, Thermo Fisher Scientific today reported 3 percent revenue growth year over year in the first quarter.

For the three months ended April 2, the company posted revenues of $2.72 billion, up from $2.63 billion a year ago, and surpassing analyst forecasts for $2.65 billion. Acquisitions added 2 percentage points to revenues, while currency translation added 1 percentage point.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.